Earlier this month, for example, BioNTech reported results with its "amplified" CAR-T BNT-211 for solid tumours, which consists of cells directed at Claudin-6 on cancer cells, coupled with an mRNA ...

The CAR T-cell therapy KYV-101 is safe, and showed preliminary signs of efficacy in patients with progressive forms of MS in ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Although CD19-directed CAR T cells can initially induce remission in 70-90% of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), post-CAR relapses are frequent. These ...

FDA has cleared an investigational new drug (IND) application to study switchable chimeric antigen receptor T cell (sCAR-T) therapy (CLBR001 + SWI019) in patients with autoimmune conditions. Patient ...

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy investigated in the ZUMA-1 trial – is the first chimeric antigen receptor (CAR) T-cell therapy recommended for ...

Researchers at Children's Hospital of Philadelphia (CHOP) developed a longitudinal atlas of neuroblastoma, a common and ...

Plant cells have several structures not found in other eukaryotes. In particular, organelles called chloroplasts allow plants to capture the energy of the Sun in energy-rich molecules; cell walls ...

Our immune systems weaken as we get older, making fewer cells that fight infection and help us recover from illness and injury. Scientists aren't completely sure why. They may have a better idea now, ...